Population Pharmacokinetic Study of Gabapentin in Iranian Healthy Volunteers Pop PK Study of Gabapentin in Iranian Healthy Volunteers
Iranian Journal of Pharmaceutical Sciences,
Vol. 18 No. 3 (2022),
1 July 2022
,
Page 223-234
https://doi.org/10.22037/ijps.v18.42667
Abstract
The objective of the study was to evaluate the pharmacokinetics of a single oral dose of 300 mg gabapentin capsule in an Iranian healthy population. The study was a standard two-way, crossover, randomized, and single-dose study with one-week washout period in 24 healthy volunteers who received 300 mg gabapentin capsules (test and reference formulation). After drug administration, blood samples were taken according to the planned times over a period of 24 hours. The plasma concentrations of gabapentin were determined using the validated high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection. All the pharmacokinetic parameters for gabapentin in healthy volunteers were calculated using nonlinear mixed-effect modeling and standard non-compartmental methods. A one-compartment model with a first-order absorption rate and first-order elimination rate with a proportional error model described the pharmacokinetics of gabapentin. Values (relative standard error (RSE) %) for first-order absorption rate constant (Ka), oral clearance (Cl/F), and apparent volume of distribution (Vd/F) were 1.08 (7.23) 1/h, 6.72(0.29) L/h, and 73.82(5.10) L. The mean estimate for non-compartmental pharmacokinetic parameters including maximum plasma concentration (Cmax), the area under the curve to the last quantifiable concentration (AUCt), and the area under the curve to the infinity (AUCinf) was calculated. Cmax for test and reference formulation was 3850 ng/mL and 3856 ng/mL respectively. The AUCt for test and reference formulation was 39549 ng. h/mL and 40249 ng. h/mL respectively. The AUCinf for test and reference formulation was 47161 ng. h/mL and 633424 ng. h/mL respectively. The median (range) for the time to peak plasma gabapentin concentration (Tmax) for the test and reference drug was 3 (1.5-6) hours and 3 (1.5-5) hours respectively. The mean (standard deviation) elimination half-life (t1/2) of gabapentin for the test and reference drug was 9.39 (2.75) hours and 8.88 (2.48) hours. They were all within the acceptable range of 80-125%, consequently, we concluded that the two gabapentin formulations were bioequivalent. Our results confirmed that the gabapentin pharmacokinetic model in the Iranian healthy population was similar to other studied populations. However, we could not find any influential covariate to explain the inter-individual variability of parameters.
- Gabapentin
- Pharmacokinetics
- Iranian population
- Healthy subjects
How to Cite
References
[2] Chang CY, Challa CK, Shah J,Eloy JD. Gabapentin in acute postoperative pain management. BioMed research international. (2014) 2014.
[3] Dougherty JA,Rhoney DH. Gabapentin: a unique anti-epileptic agent. Neurological research. (2001) 23 (8): 821-9.
[4] Rose M,Kam P. Gabapentin: pharmacology and its use in pain management. Anaesthesia. (2002) 57 (5): 451-62.
[5] Crisologo PA, Monson EK,Atway SA. Gabapentin as an adjunct to standard postoperative pain management protocol in lower extremity surgery. The Journal of Foot and Ankle Surgery. (2018) 57 (4): 781-4.
[6] Hassan HIC, Brennan F, Collett G, Josland EA,Brown MA. Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. Journal of pain and symptom management. (2015) 49 (4): 782-9.
[7] Honarmand A, Safavi M,Zare M. Gabapentin: an update of its pharmacological properties and therapeutic use in epilepsy. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. (2011) 16 (8): 1062.
[8] Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. The Lancet. (2005) 366 (9488): 818-24.
[9] Berry DJ, Beran RG, Plunkeft MJ, Clarke LA,Hung WT. The absorption of gabapentin following high dose escalation. Seizure. (2003) 12 (1): 28-36.
[10] Stewart BH, Kugler AR, Thompson PR,Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharmaceutical research. (1993) 10 (2): 276-81.
[11] Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical pharmacokinetics. (2010) 49 (10): 661-9.
[12] Lal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, et al. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. The Journal of Clinical Pharmacology. (2013) 53 (1): 29-40.
[13] Ouellet D, Bockbrader HN, Wesche DL, Shapiro DY,Garofalo E. Population pharmacokinetics of gabapentin in infants and children. Epilepsy research. (2001) 47 (3): 229-41.
[14] Abib Jr E, Duarte L, Pereira R, Pozzebon J, Tosetti D, et al. Gabapentin Bioequivalence Study: Quantification By Liquid Chromatography Coupled To Mass Spectrometry. Journal of Bioequivalence and Bioavailability. (2011).
[15] Almeida S, Filipe A, Almeida A, Antonijoan R, García-Gea C, et al. Comparative Study on the Bioequivalence of Two Different Gabapentin Formulations. Arzneimittelforschung. (2006) 56 (02): 59-63.
[16] Cho H, Kang H,Lee Y. Pharmacokinetics and bioequivalence evaluation of two gabapentin preparations after a single oral dose in healthy Korean volunteers. International Journal of Clinical Pharmacology & Therapeutics. (2006) 44 (8).
[17] Mak W, Tan S, Wong J, Chin S,Lim A. Pharmacokinetic comparison of two gabapentin formulations in healthy volunteers. J Bioequiv Availab. (2016) 8: 055-8.
[18] Wittayalertpanya S, Chompootaweep S, Thaworn N, Khemsri W,Intanil N. Bioequivalence study of two different formulations of 300 mg gabapentin capsule in Thai healthy volunteers. Thai J Pharm Sci. (2008) 32: 70-6.
[19] Yamamoto PA, Benzi JR, Azeredo FJ, Dach F, Ianhez Júnior E, et al. Pharmacogenetics‐based population pharmacokinetic analysis of gabapentin in patients with chronic pain: Effect of OCT 2 and OCTN 1 gene polymorphisms. Basic & clinical pharmacology & toxicology. (2019) 124 (3): 266-72.
[20] Costa ACC, de Lima Benzi JR, Yamamoto PA, de Freitas MCF, de Paula FJA, et al. Population pharmacokinetics of gabapentin in patients with neuropathic pain: Lack of effect of diabetes or glycaemic control. British Journal of Clinical Pharmacology. (2021) 87 (4): 1981-9.
[21] Carlsson KC, van de Schootbrugge M, Eriksen HO, Moberg ER, Karlsson MO, et al. A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling. Therapeutic drug monitoring. (2009) 31 (1): 86-94.
[22] Jalalizadeh H, Souri E, Tehrani MB,Jahangiri A. Validated HPLC method for the determination of gabapentin in human plasma using pre-column derivatization with 1-fluoro-2, 4-dinitrobenzene and its application to a pharmacokinetic study. Journal of Chromatography B. (2007) 854 (1-2): 43-7.
[23] Uvarova N, Eremenko N, Ramenskaya G, Goryachev D,Smirnov V. Comparison of FDA (2018) and EAEU Regulatory Requirements for Bioanalytical Method Validation. Pharmaceutical Chemistry Journal. (2019) 53 (8): 759-65.
[24] Chauvin J, Ayral G,Traynard P. COSSAC (COnditional Sampling use for Stepwise Approach based on Correlation tests) method for covariate search. In: Journal of Pharmacokinetics and Pharmacodynamics: Springer/Plenum Publishers 233 Spring St, New York, Ny 10013 USA. (2018).pp. S33-S.
[25] Cohen AS,Cho S-J. Information criteria. Handbook of item response theory: Models, statistical tools, and applications. (2016).
[26] Bahrami G,Kiani A. Sensitive high-performance liquid chromatographic quantitation of gabapentin in human serum using liquid–liquid extraction and pre-column derivatization with 9-fluorenylmethyl chloroformate. Journal of Chromatography B. (2006) 835 (1-2): 123-6.
[27] Bahrami G,Mohammadi B. Sensitive microanalysis of gabapentin by high-performance liquid chromatography in human serum using pre-column derivatization with 4-chloro-7-nitrobenzofurazan: Application to a bioequivalence study. Journal of Chromatography B. (2006) 837 (1-2): 24-8.
[28] Tran P, Yoo H-D, Ngo L, Cho H-Y,Lee Y-B. Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. Journal of pharmacokinetics and pharmacodynamics. (2017) 44 (6): 567-79.
[29] Gidal BE, Radulovic L, Kruger S, Rutecki P, Pitterle M, et al. Inter-and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy research. (2000) 40 (2-3): 123-7.
[30] Mansoor A,Mahabadi N. Volume of distribution. StatPearls [Internet]. (2021).
[31] Ahmed GF, Bathena SPR, Brundage RC, Leppik IE, Conway JM, et al. Pharmacokinetics and saturable absorption of gabapentin in nursing home elderly patients. The AAPS journal. (2017) 19 (2): 551-6.
[32] Boyd RA, Türck D, Abel RB, Sedman AJ,Bockbrader HN. Effects of age and gender on single‐dose pharmacokinetics of gabapentin. Epilepsia. (1999) 40 (4): 474-9.
[33] Goodman CW,Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA internal medicine. (2019) 179 (5): 695-701.
[34] Tjandrawinata RR, Setiawati E, Putri RSI, Yunaidi DA, Amalia F, et al. Single dose pharmacokinetic equivalence study of two gabapentin preparations in healthy subjects. Drug design, development and therapy. (2014) 8: 1249.
- Abstract Viewed: 547 times
- IJPS- Vol 18- Issue 3- Page 223-234 Downloaded: 106 times